The ability of cPvMSP1-Pvs25 to maintain robust IFN-γ responses to cPvMSP1 when conjugated to the Pvs25 protein is encouraging for the blood stage component of this vaccine candidate, as several reports have indicated that high frequencies of IFN-γ secreting CD4+ T cells provide protection from malaria in humans (Roestenberg et al., 2009; White et al., 2013; King and Lamb, 2015). Here, CD4 is linked to malaria.